Need professional-grade analysis? Visit stockanalysis.com
$158.04M
N/A
N/A
N/A
ProQR Therapeutics BV (PRQR) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.63, down 6.86% from the previous close.
Over the past year, PRQR has traded between a low of $1.37 and a high of $3.05. The stock has gained 5.8% over this period. It is currently 46.6% below its 52-week high.
ProQR Therapeutics BV has a market capitalization of $158.04M.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Side-by-side comparison against top Healthcare peers.